99mTc-tazobactam, a novel infection imaging agent: Radiosynthesis, quality control, biodistribution, and infection imaging studies.
The radiolabeled drug99mTc-tazobactam (99mTc-TZB) was developed and assessed as an infection imaging agent in Pseudomonas aeruginosa and Salmonella enterica infection-induced animal models by comparing with inflammation induced animal models. Radiosynthesis of99mTc-TZB was assessed while changing ligand concentration, reducing agent concentration, pH, and reaction time while keeping radioactivity constant (~370 MBq). Percent labeling of the resulting complex was measured using paper chromatography and instant thin layer chromatography. The analysis of the99mTc-TZB complex indicated >95% labeling yield and electrophoresis revealed complex is neutral in nature. The biodistribution study also showed predominantly renal excretion; however liver, stomach, and intestine also showed slight tracer agent uptake. The agent significantly accumulated in Pseudomonas aeruginosa and Salmonella enterica infection induced tissues 3.58 ± 0.26% and 2.43 ± 0.42% respectively at 1 hour postinjection. The inflamed tissue failed to uptake noticeable activity at 1 hour time point. The scintigraphic study results were found in accordance with biodistribution pattern. On the basis of our preliminary results, the newly developed99mTc-TZB can be used to diagnose bacterial infection and to discriminate between infected and inflamed tissues.
Institute of Nuclear Medicine Oncology and Radiotherapy (INOR), Abbottabad, Pakistan.|Department of Chemistry, Government College University, Faisalabad-38000, Pakistan.
Rashid
R
Rasheed
Department of Chemistry, Government College University, Faisalabad-38000, Pakistan.
Syed Ali Raza
0000-0002-2172-9066
SAR
Naqvi
Institute of Nuclear Medicine Oncology and Radiotherapy (INOR), Abbottabad, Pakistan.
Syed Jawad Hussain
SJH
Gillani
Department of Chemistry, Government College University, Faisalabad-38000, Pakistan.
Ameer Fawad
AF
Zahoor
Institute of Nuclear Medicine Oncology and Radiotherapy (INOR), Abbottabad, Pakistan.
Asif
A
Jielani
Department of Pharmacy, Clinical Practice, COMSATS Institute of Information Technology, Abbottabad, Pakistan.
Nidda
N
Saeed
D000818:Animals; D060326:Chemistry Techniques, Synthetic; D006863:Hydrogen-Ion Concentration; D008024:Ligands; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D011552:Pseudomonas Infections / Q000000981:diagnostic imaging*; D011550:Pseudomonas aeruginosa / Q000502:physiology; D011786:Quality Control; D011817:Rabbits; D011854:Radiochemistry; D011877:Radionuclide Imaging / Q000379:methods*; D051381:Rats; D019163:Reducing Agents / Q000737:chemistry; D012480:Salmonella Infections / Q000000981:diagnostic imaging*; D019779:Salmonella enterica / Q000502:physiology; D000078142:Tazobactam; D013667:Technetium / Q000737:chemistry*; D014018:Tissue Distribution
D008024:Ligands; D019163:Reducing Agents; D013667:Technetium; D010397:Penicillanic Acid; D000078142:Tazobactam
99mTc-tazobactam; Beta-lactamases; P. aeruginosa; Radipharmaceuticals; S. enterica; infection diagnosis